Body Central Beats on Both Top and Bottom Lines

Seth Jayson, The Motley Fool
Updated

Body Central (NAS: BODY) reported earnings on Mar. 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Body Central beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share grew significantly.

Gross margins dropped, operating margins grew, net margins improved.

Revenue details
Body Central chalked up revenue of $80.7 million. The five analysts polled by S&P Capital IQ anticipated sales of $79.7 million on the same basis. GAAP reported sales were 20% higher than the prior-year quarter's $67.1 million.

anImage
anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.38. The five earnings estimates compiled by S&P Capital IQ predicted $0.37 per share. GAAP EPS of $0.38 for Q4 were 124% higher than the prior-year quarter's $0.17 per share.

anImage
anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 34.7%, 210 basis points worse than the prior-year quarter. Operating margin was 12.2%, 320 basis points better than the prior-year quarter. Net margin was 7.6%, 350 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $86.2 million. On the bottom line, the average EPS estimate is $0.39.

Next year's average estimate for revenue is $354.3 million. The average EPS estimate is $1.49.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 26 members out of 28 rating the stock outperform, and two members rating it underperform. Among five CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Body Central a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Body Central is buy, with an average price target of $29.20.

While many retailers continue to struggle in these tough economic time, a select few are changing the face of the business, and reaping outsized rewards. Is Body Central the right stock for you? Read "The Death of Wal-Mart: The Real Cash Kings Changing the Face of Retail" and decide. Click here for instant access to this free report.

At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement